Cargando…
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
OBJECTIVE: Currently, there are no data available on SARS-CoV-2 vaccine responses in pediatric-onset multiple sclerosis (POMS), and little is known about the course of SARS-CoV-2 infection in this age group. We therefore investigated humoral immune responses after COVID-19 vaccination and/or infecti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979636/ https://www.ncbi.nlm.nih.gov/pubmed/36966598 http://dx.doi.org/10.1016/j.pediatrneurol.2023.02.017 |
_version_ | 1784899763315933184 |
---|---|
author | Breu, Markus Lechner, Christian Schneider, Lisa Tobudic, Selma Winkler, Stefan Siegert, Sandy Baumann, Matthias Seidl, Rainer Berger, Thomas Kornek, Barbara |
author_facet | Breu, Markus Lechner, Christian Schneider, Lisa Tobudic, Selma Winkler, Stefan Siegert, Sandy Baumann, Matthias Seidl, Rainer Berger, Thomas Kornek, Barbara |
author_sort | Breu, Markus |
collection | PubMed |
description | OBJECTIVE: Currently, there are no data available on SARS-CoV-2 vaccine responses in pediatric-onset multiple sclerosis (POMS), and little is known about the course of SARS-CoV-2 infection in this age group. We therefore investigated humoral immune responses after COVID-19 vaccination and/or infection in POMS. METHODS: We retrospectively analyzed seroconversion rates and SARS-CoV-2–specific antibody levels in 30 POMS and one pediatric CIS patient treated with no disease-modifying therapy (no DMT), immunomodulatory DMT (IM-DMT), or immunosuppressive DMT (IS-DMT) from two Austrian MS centers. RESULTS: The median age at MS onset was 15.39 years (interquartile range [IQR]: 1.97). The median age at the first COVID-19 vaccination was 17.43 years (IQR: 2.76). After two vaccine doses, seroconversion (≥0.8 BAU/ml) was reached in 25 of 28 patients (89.3%). All patients with no DMT or IM-DMT generated robust immune responses to vaccination (seroconversion: no DMT: 6/6, IM-DMT: 7/7 [100%]; median titers: no DMT: 2075 BAU [IQR: 1268.50], IM-DMT: 2500 BAU [IQR: 0]). In the IS-DMT group, seroconversion was achieved in 12 of 14 patients (80%), and median titers were 50.8 BAU (IQR 254.63). Titers were significantly higher in no DMT versus IS-DMT (P = 0.012) and in IM-DMT versus IS-DMT (P = 0.001). Infection with SARS-CoV-2 occurred in 11 of 31 patients, and symptoms were mild in all cases. One relapse occurred after infection, but no relapses were documented after vaccination. CONCLUSIONS: Generally, mRNA vaccinations were well tolerated in POMS patients with and without DMT. Immune response was significantly reduced in patients treated with IS-DMT. No unexpected adverse events or relapses related to vaccinations were observed. |
format | Online Article Text |
id | pubmed-9979636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99796362023-03-03 Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis Breu, Markus Lechner, Christian Schneider, Lisa Tobudic, Selma Winkler, Stefan Siegert, Sandy Baumann, Matthias Seidl, Rainer Berger, Thomas Kornek, Barbara Pediatr Neurol Research Paper OBJECTIVE: Currently, there are no data available on SARS-CoV-2 vaccine responses in pediatric-onset multiple sclerosis (POMS), and little is known about the course of SARS-CoV-2 infection in this age group. We therefore investigated humoral immune responses after COVID-19 vaccination and/or infection in POMS. METHODS: We retrospectively analyzed seroconversion rates and SARS-CoV-2–specific antibody levels in 30 POMS and one pediatric CIS patient treated with no disease-modifying therapy (no DMT), immunomodulatory DMT (IM-DMT), or immunosuppressive DMT (IS-DMT) from two Austrian MS centers. RESULTS: The median age at MS onset was 15.39 years (interquartile range [IQR]: 1.97). The median age at the first COVID-19 vaccination was 17.43 years (IQR: 2.76). After two vaccine doses, seroconversion (≥0.8 BAU/ml) was reached in 25 of 28 patients (89.3%). All patients with no DMT or IM-DMT generated robust immune responses to vaccination (seroconversion: no DMT: 6/6, IM-DMT: 7/7 [100%]; median titers: no DMT: 2075 BAU [IQR: 1268.50], IM-DMT: 2500 BAU [IQR: 0]). In the IS-DMT group, seroconversion was achieved in 12 of 14 patients (80%), and median titers were 50.8 BAU (IQR 254.63). Titers were significantly higher in no DMT versus IS-DMT (P = 0.012) and in IM-DMT versus IS-DMT (P = 0.001). Infection with SARS-CoV-2 occurred in 11 of 31 patients, and symptoms were mild in all cases. One relapse occurred after infection, but no relapses were documented after vaccination. CONCLUSIONS: Generally, mRNA vaccinations were well tolerated in POMS patients with and without DMT. Immune response was significantly reduced in patients treated with IS-DMT. No unexpected adverse events or relapses related to vaccinations were observed. The Author(s). Published by Elsevier Inc. 2023-06 2023-03-02 /pmc/articles/PMC9979636/ /pubmed/36966598 http://dx.doi.org/10.1016/j.pediatrneurol.2023.02.017 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Research Paper Breu, Markus Lechner, Christian Schneider, Lisa Tobudic, Selma Winkler, Stefan Siegert, Sandy Baumann, Matthias Seidl, Rainer Berger, Thomas Kornek, Barbara Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title | Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title_full | Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title_fullStr | Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title_full_unstemmed | Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title_short | Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis |
title_sort | humoral immune response following sars-cov-2 mrna vaccination and infection in pediatric-onset multiple sclerosis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979636/ https://www.ncbi.nlm.nih.gov/pubmed/36966598 http://dx.doi.org/10.1016/j.pediatrneurol.2023.02.017 |
work_keys_str_mv | AT breumarkus humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT lechnerchristian humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT schneiderlisa humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT tobudicselma humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT winklerstefan humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT siegertsandy humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT baumannmatthias humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT seidlrainer humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT bergerthomas humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis AT kornekbarbara humoralimmuneresponsefollowingsarscov2mrnavaccinationandinfectioninpediatriconsetmultiplesclerosis |